Search

everythinglearnresearchcommunity

for

Search:↓

Trichotillomania is often misdiagnosed as alopecia areata and can be treated effectively with N-acetylcysteine and psychotropic drugs.

New targeted therapies for hair loss from alopecia areata show promise, with personalized treatment expected in the future.

Wearing wigs or hairpieces improves self-esteem, adaptability, and competence in women with alopecia areata.

White hairs often regrow in alopecia areata patches.

Hair color is not a risk factor for developing alopecia areata.

OCT can detect hidden hair follicles in alopecia areata, indicating potential hair regrowth.

Certain gene variations in EGF and EGFR may increase the risk of alopecia areata in Koreans.

Higher levels of certain DNAs in blood may indicate hair follicle damage in alopecia areata patients.

Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.

Alopecia areata is relatively common in children, has a variable course, and shows different responses to treatment; thyroid testing is recommended for those affected.

Alopecia areata, a common autoimmune hair loss condition, often runs in families.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Current treatments for alopecia show no significant long-term benefits.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

Minoxidil helps hair regrowth in alopecia patients, with 16 having good results and no side effects.

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

Baricitinib is effective and safe for treating severe alopecia areata.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Using patients' own fat-derived cells to treat alopecia areata significantly improved hair growth and was safe.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

People with Major Depressive Disorder have a higher chance of getting Alopecia Areata, and vice versa; antidepressants may lower this risk.

Trichoscopy helps tell apart alopecia areata and trichotillomania in Asians by looking at specific hair and scalp features.

Alopecia areata is linked to thyroid autoimmunity but not type 1 diabetes.

Patients with Alopecia areata have fewer specific immune cells that normally regulate the immune system, which may contribute to the condition.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Lupus can look like hair loss from alopecia areata but needs different treatment.

People with alopecia areata often have higher rates of allergies and autoimmune diseases.